Femara 2.5mg 20 tab

Quantity-20 tablets

Femara-2.5mg per tablet

What is Femara?

Femara, scientifically known as letrozole, is a medication classified as an aromatase inhibitor. From a scientific standpoint, it is a pharmaceutical compound primarily designed and employed for the treatment of hormone receptor-positive breast cancer in postmenopausal women. Its mechanism of action is rooted in its ability to inhibit the enzyme aromatase, a key player in the conversion of androgens (specifically, adrenal androgens) into estrogens (primarily, estradiol). This enzymatic inhibition effectively reduces the overall levels of circulating estrogens in the body.

In hormone receptor-positive breast cancer cases, the presence of estrogen can stimulate tumor growth. Therefore, by reducing estrogen levels, Femara acts as an adjuvant therapy to slow down or inhibit the progression of such breast cancers. This function is achieved by suppressing the estrogen-dependent cellular pathways that drive tumor proliferation, ultimately leading to an inhibitory effect on the growth of hormone-responsive breast cancer cells.

Femara is administered orally in the form of tablets and is typically prescribed as part of a comprehensive treatment plan for postmenopausal women diagnosed with hormone receptor-positive breast cancer. Clinical studies have demonstrated its efficacy in reducing the risk of cancer recurrence, enhancing disease-free survival rates, and, in some cases, facilitating tumor regression.

Femara Info Based off of Research

1. Reduction in Tumor Size: Femara inhibits the activity of the aromatase enzyme, which plays a key role in estrogen synthesis. By reducing estrogen levels, it helps shrink estrogen-dependent tumors in hormone receptor-positive breast cancer.
2. Improved Disease-Free Survival: Clinical studies have shown that treatment with Femara can lead to improved disease-free survival rates in women with early-stage hormone receptor-positive breast cancer, reducing the risk of cancer recurrence.
3. Lower Risk of Distant Metastasis: Femara has been associated with a lower risk of cancer metastasis to distant sites in the body, which can improve long-term prognosis.
4. Preservation of Healthy Breast Tissue: By inhibiting estrogen action, Femara can help prevent the development of new breast tumors in the unaffected breast, preserving healthy breast tissue.
5. Adjuvant Therapy: Femara is often used as adjuvant therapy following surgery and other treatments (such as radiation or chemotherapy) to further reduce the risk of cancer recurrence.
6. Reduced Risk of Second Primary Cancers: Some studies suggest that Femara may lower the risk of developing a second primary breast cancer in the opposite breast.